Key Points {#d30e230}
==========

While there is a substantial body of literature on the comparative healthcare costs of biologics used to treat rheumatoid arthritis (RA), nearly all of these investigations have been exclusively focused on anti-tumor necrosis factor-α (anti-TNF) agents in the setting of first-line biologic treatment.This study compared healthcare costs between RA patients treated with infused biologics after previously using at least one other biologic agent.Using a large US administrative claims dataset, adult RA patients initiating an infused biologic (abatacept, infliximab, tocilizumab) between January 1, 2010 and January 1, 2012 (initiation = index) were identified.A variable-length follow-up period after index was used to measure per-patient per-month healthcare costs, including biologic costs, RA-related healthcare costs, and all-cause healthcare costs.Among RA patients treated with infused biologics after previously using at least one other biologic, patients treated with tocilizumab had the lowest real-world healthcare costs.

Introduction {#Sec1}
============

In the treatment of rheumatoid arthritis (RA), biologic agents are recommended for patients who have experienced an inadequate response to conventional disease modifying anti-rheumatic drugs \[[@CR1]\]. Among the biologic agents currently approved for treatment of RA, seven may be self-administered through subcutaneous injection (abatacept, adalimumab, anakinra, certolizumab, etanercept, golimumab, and tocilizumab) and five have to be administered through intravenous infusion by a healthcare provider (abatacept, golimumab, infliximab, tocilizumab, and rituximab). The choice between self-administered and healthcare provider-administered agents can depend on a number of factors, including patient and provider preferences, reimbursement, and insurance coverage policies \[[@CR2]--[@CR4]\].

The American College of Rheumatology recommends the use of anti-tumor necrosis factor-α (anti-TNF) therapies as the first-line option when initiating a patient with RA on biologic therapy \[[@CR1]\]. Thus, most infused biologics, three of which are not anti-TNF therapies, are usually used in patients who have previously used at least one other biologic agent. Among such patients for whom a biologic with an infused route of administration has been chosen, the available therapies differ widely with respect to mechanism of action, frequency of administration, and variation in dosing options \[[@CR5]--[@CR8]\].

US payers are increasingly relying on real-world, comparative healthcare utilization and cost data when making decisions related to the coverage of therapies \[[@CR9], [@CR10]\]. While there is a substantial body of literature on the comparative healthcare costs of biologics used to treat RA, nearly all of these investigations have been exclusively focused on anti-TNF agents in the setting of first-line biologic treatment \[[@CR11]--[@CR19]\]. Though two prior studies have examined healthcare costs among patients treated with the infused biologics abatacept, infliximab, and rituximab, both were intended to be purely descriptive and made no attempts to adjust for inherent differences in patient characteristics that may drive differences in healthcare costs \[[@CR20], [@CR21]\]. Furthermore, to date, no prior studies have examined the costs of RA patients treated with tocilizumab. Thus, the objective of this retrospective, observational cohort study was to compare healthcare costs between RA patients treated with infused biologics after previously using at least one other biologic agent. This study focuses specifically on infused biologics to provide specific, comparative information on these agents to inform treatment choice when circumstances such as insurance coverage or patient/provider preferences necessitate the use of this route of administration.

Methods {#Sec2}
=======

Data and Setting {#Sec3}
----------------

This was a retrospective, observational cohort study based on US administrative claims data extracted from the Truven Health MarketScan^®^ Commercial Claims and Encounters (Commercial) and Medicare Supplemental and Coordination of Benefits (Medicare Supplemental) databases. These databases comprise enrollment information, demographic information, and inpatient medical, outpatient medical, and outpatient pharmacy claims data collected from over 300 large self-insured US employers and over 25 US health plans. The Commercial database includes information on individuals who are under the age of 65 and are the primary insured or a spouse or dependent thereof. The Medicare Supplemental database includes information for individuals who are Medicare eligible and have a supplemental insurance paid for by their current or former employer. The study databases contained data for over 40 million unique individuals in 2011. These databases have been used in multiple studies related to RA \[[@CR22]\].

The study databases satisfy the conditions set forth in Sections 164.514 (a)--(b)1ii of the *Health Insurance Portability and Accountability Act* of 1996 privacy rule regarding the determination and documentation of statistically de-identified data. Because this study used only de-identified patient records and does not involve the collection, use, or transmittal of individually identifiable data, Institutional Review Board approval to conduct this study was not necessary.

As described in greater detail below, study variables were measured from the database using enrollment records, International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) codes, Current Procedural Technology, 4th edition (CPT-4^®^) codes, Healthcare Common Procedure Coding System (HCPCS) codes, and National Drug Codes (NDCs), as appropriate \[[@CR23]\].

Patient Selection Criteria {#Sec4}
--------------------------

Patients were included in the analysis if they met all of the following selection criteria: initiated an infused biologic agent (abatacept, infliximab, or tocilizumab) between January 1, 2010 and January 1, 2012 (the dates of initiation for biologic agents used during this period were designated as the index dates); used at least one other biologic (either subcutaneous or an intravenous agent) at any time prior to the index date; had at least one inpatient or non-diagnostic outpatient medical claim (i.e., excluding medical claims such as radiology and venipuncture, which may represent services that are used to diagnose or rule out the presence of a condition) with a diagnosis of RA (ICD-9-CM code 714.0x) between January 1, 2009 and March 31, 2012; were aged 18 years or older on the index date; were continuously enrolled, according to insurance enrollment records, for at least 6 months pre-index (designated as the baseline period) and at least 3 months post-index; and had no medical claims with diagnosis codes for any non-RA indication of biologic agents (ankylosing spondylitis, chronic lymphocytic leukemia, Crohn's disease, juvenile idiopathic arthritis, polyarteritis nodosa, non-Hodgkin's lymphoma, plaque psoriasis, psoriatic arthritis, ulcerative colitis, or Wegener's granulomatosis) within the baseline period. Patients initiating treatments with induction doses were not necessarily required to complete the induction phase of treatment in order to be retained in the analysis.

An episode-based study design was used wherein patients were allowed to contribute multiple observations to the dataset, one for each infused biologic they initiated sequentially during the study period. Thus, patients were followed forward in time after their first qualifying infused biologic initiation to capture all subsequent episodes of infused biologic use. Episodes of infused biologic use began with initiation of a new infused biologic, with follow-up extending until the first occurrence of a 90-day gap in treatment with the initiated biologic, switch to a different biologic, insurance disenrollment, or the end of the study period (March 31, 2012).

Rituximab was not included in the analyses because of unique dosing intervals, which make it difficult to determine treatment discontinuation using a claims database. Specifically, the recommended frequency of rituximab re-infusions was initially based on clinical evaluation but later updated to be every 24 weeks or based on clinical evaluation, but not sooner than every 16 weeks. Because the magnitude of estimated healthcare costs incurred while a patient is being treated with a biologic is highly sensitive to the time period over which a patient is determined to be 'on treatment,' censoring follow-up at a 90-day gap may artificially inflate the cost of care for RA patients who are being treated with rituximab based on clinical evaluation.

Healthcare Cost Outcomes {#Sec5}
------------------------

The study outcomes were per-patient per-month (PPPM) healthcare costs measured during the follow-up. PPPM is calculated by dividing the total costs incurred during the episode by the number of days in the episode and then multiplying the resultant per-day costs by 30 to normalize costs to a 30-day (monthly) unit. The use of PPPM costs therefore accounts for the fact that patient follow-up is not necessarily equal for all patients. Healthcare costs were classified into (1) biologic costs (biologic drug + administration), (2) RA-related healthcare costs, which included costs for drugs used in symptomatic treatment \[biologic drug + administration + non-biologic RA drugs (methotrexate, hydroxychloroquine, leflunomide, minocycline, sulfasalazine, cyclosporine, azathioprine, gold sodium thiomalate, non-steroidal anti-inflammatory drugs, corticosteroids, other analgesics) + medical claims coded with ICD-9-CM diagnosis codes for RA\], and (3) all-cause healthcare costs (all pharmacy and medical claims). Healthcare costs were measured from the payment field on adjudicated medical and pharmacy insurance claims within the database. These costs include the gross covered payments for all healthcare services or products (i.e., the amount eligible for payment after applying pricing guidelines such as fee schedules and discounts, but including deductibles, copayments, and coordination of benefits). Healthcare costs were expressed in 2011 constant US dollars, adjusted using the Medical Care component of the Consumer Price Index \[[@CR24]\].

Covariates {#Sec6}
----------

The study covariates included patient demographics and clinical characteristics thought to potentially confound the relationship between the healthcare costs outcomes and biologic agent. Patient demographics were measured at index and are listed in Table [1](#Tab1){ref-type="table"}. Patient clinical characteristics were measured throughout the baseline period and are listed in Table [2](#Tab2){ref-type="table"} \[[@CR25], [@CR26]\]. The clinical characteristics included an administrative claims-based RA severity score \[[@CR27]\]. This score has been shown to have moderate correlations with a previously validated records-based index of severity that had established construct and convergent validity with the Disease Activity Score in 28 Joints (DAS28). The Claims-based Index for Rheumatoid Arthritis Severity (CIRAS) is a numerical value that is computed on the basis of orders for inflammatory markers, number of platelet counts and chemistry panels ordered, rheumatoid factor, rehabilitation visits, age and gender, presence of Felty's syndrome, and number of rheumatology visits. Details on the algorithm can be found in Ting et al. \[[@CR27]\]. The clinical characteristics also included two administrative claims-based indices of general health---the number of unique ICD-9-CM codes recorded on claims in the baseline period and the number of unique NDCs in the baseline period---that have been shown to correlate with healthcare costs and adverse outcomes such as emergency room visits and hospitalizations \[[@CR25]\].Table 1Patient demographicsTCZ (*N* = 1,090)ABA (*N* = 1,759)INF (*N* = 922)Age (mean ± SD)54.7 ± 12.355.4 ± 12.853.5 ± 13.2Female (%)83.183.281.2Geographic region (%) Northeast12.311.813.3 North Central27.328.122.2 South39.042.043.5 West20.617.120.0 Unknown0.71.01.0Insurance plan type (%) Comprehensive11.013.812.4 EPO1.71.91.3 HMO15.214.116.7 POS7.98.26.9 PPO53.953.255.0 POS with capitation0.90.90.8 CDHP3.72.92.4 HDHP1.71.81.6 Unknown4.03.22.9Population density (%) Urban84.985.283.8 Rural14.413.815.2 Unknown0.71.01.0Year of index (%) 201033.448.947.7 201166.651.152.3*ABA* abatacept, *CDHP* Consumer Directed Health Plan, *EPO* Exclusive Provider Organization, *HDHP* High Deductible Health Plan, *HMO* Health Maintenance Organization, *INF* infliximab, *POS* Point of Service, *PPO* Preferred Provider Organization, *SD* standard deviation, *TCZ* tocilizumabTable 2Patient baseline clinical characteristicsTCZ (*N* = 1,090)ABA (*N* = 1,759)INF (*N* = 922)Median follow-up in days251280269CIRAS (mean ± SD)3.6 ± 0.93.5 ± 1.03.6 ± 1.1NSAIDs (%)38.539.341.9Corticosteroids (%)80.878.676.7Analgesics (%)63.958.656.9Non-biologic DMARDs (mean ± SD)0.9 ± 0.70.9 ± 0.71.0 ± 0.7Non-biologic DMARDs (%)\* Methotrexate50.350.961.2 Hydroxychloroquine13.316.416.6 Leflunomide14.113.315.1 Minocycline1.11.30.9 Sulfasalazine5.06.66.4 Cyclosporine0.20.20.3 Azathioprine5.43.22.2 Gold sodium thiomalate0.10.00.2Extra-articular disease\*\* (%)5.54.53.4DCI (mean ± SD)1.4 ± 0.91.4 ± 0.91.4 ± 0.9Number of unique 3-digit ICD-9-CM (mean ± SD)21.7 ± 16.618.8 ± 14.418.7 ± 14.6Number of unique NDCs (mean ± SD)21.2 ± 15.717.8 ± 12.318.5 ± 13.6Immediately prior drug = anti-TNF (%)49.585.872.5*ABA* abatacept, *CIRAS* Claims-based Index for Rheumatoid Arthritis Severity, *DCI* Deyo--Charlson Comorbidity Index, *DMARD* disease-modifying antirheumatic drug, *ICD-9-CM* International Classification of Diseases, 9th Revision, Clinical Modification, *INF* infliximab, *NDC* National Drug Code, *NSAID* non-steroidal anti-inflammatory drug, *SD* standard deviation, *TCZ* tocilizumab, *TNF* tumor necrosis factor-α\* The overall number of non-biologic DMARDs was adjusted for in the models as opposed to the individual non-biologic DMARD indicators\*\* Rheumatoid nodules, Sjögren's syndrome, retinal vasculitis, other vasculitis, Felty's syndrome, or rheumatoid lung

Statistical Analyses {#Sec7}
--------------------

Bivariate analyses were used to display summary statistics for the variable distributions, stratified by infused biologic agent. Multivariable generalized estimating equations (GEE) models---which accounted for the possibility of multiple observations per patient---were used to compare the healthcare cost outcomes between the infused biologic agents, adjusting for patient demographics and clinical characteristics listed in Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"} \[[@CR28]--[@CR30]\]. These models used an independent covariance structure, log link, and gamma distribution. Predicted adjusted incremental costs and their associated 95 % confidence intervals were obtained via least squares means calculated in the framework of the GEE model relating costs to the covariates. All analyses were performed using SAS version 9.2 (Cary, NC, USA). *P* values \<0.05 were considered, a priori, to be statistically significant. *P* values are reported only for multivariable-adjusted results, as these are the only analyses on which inferences were based.

Results {#Sec8}
=======

Patient Characteristics {#Sec9}
-----------------------

Figure [1](#Fig1){ref-type="fig"} displays the sample attrition associated with the application of each study inclusion and exclusion criterion. The final sample comprised 3,771 infused biologic initiations.Fig. 1Sample selection attrition. *RA* rheumatoid arthritis

Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"} display patients' demographics and baseline clinical characteristics, respectively, stratified by infused biologic agent. The average patient age differed little across the biologics, ranging from 53.5 years in infliximab-treated patients to 55.4 years in abatacept-treated patients. The proportion of females also differed little across the biologics, ranging from 81.2 % in infliximab-treated patients to 83.2 % in abatacept-treated patients. The median follow-up ranged from 251 days among tocilizumab-treated patients to 280 days among abatacept-treated patients. Tocilizumab-treated patients had the numerically greatest proportions of patients with baseline use of corticosteroids, baseline use of analgesics, and presence of extra-articular disease, and the numerically greatest values of the number of unique 3-digit ICD-9-CM diagnosis codes and number of unique NDCs, all of which are indicative that tocilizumab-treated patients had poorer baseline health status than abatacept- and infliximab-treated patients.

Healthcare Cost Outcomes {#Sec10}
------------------------

Table [3](#Tab3){ref-type="table"} displays unadjusted PPPM biologic and RA-related healthcare utilization and costs. The mean PPPM \[standard deviation (SD)\] total RA-related healthcare costs were \$2,815 (\$3,615) for tocilizumab-treated patients, \$2,936 (\$2,038) for abatacept-treated patients, and \$3,720 (\$3,713) for infliximab-treated patients. The majority of RA-related healthcare costs were driven by the cost of the biologic, accounting for 78.2 % of the RA-related healthcare costs among tocilizumab-treated patients, 88.4 % among abatacept-treated patients, and 87.2 % among infliximab-treated patients. The mean (SD) count of biologic administrations was 1.0 (0.2) for tocilizumab-treated patients, 1.2 (0.5) for abatacept-treated patients, and 1.0 (0.5) for infliximab-treated patients.Table 3Unadjusted per-patient per-month biologic and RA-related healthcare utilization and costsTCZ (*N* = 1,090)ABA (*N* = 1,759)INF (*N* = 922)MeanSDMeanSDMeanSDInpatient admissions Count0.0±0.10.0±0.10.0±0.1 Cost\$282±\$3,196\$106±\$893\$211±\$1,652Emergency room visits Count0.0±0.10.0±0.10.0±0.1 Cost\$6±\$54\$5±\$39\$4±\$37Outpatient office visits Count0.7±0.60.7±0.60.7±0.8 Cost\$67±\$88\$60±\$69\$63±\$69Other outpatient services Count3.7±3.33.3±3.63.3±3.7 Cost\$164±\$446\$109±\$317\$132±\$1,047Outpatient prescription claims Count2.5±1.22.7±1.32.6±1.7 Cost\$2,295±\$1,573\$2,657±\$1,749\$3,309±\$2,838Biologic DMARDs Count of biologic administrations1.0±0.21.2±0.51.0±0.5 Cost of biologic drug\$2,004±\$1,469\$2,356±\$1,693\$2,979±\$2,727 Cost of biologic administration\$197±\$163\$240±\$190\$266±\$281Total cost of biologic drug + administration Insurer-paid\$2,105±\$1,509\$2,469±\$1,685\$3,107±\$2,792 Patient-paid\$97±\$152\$127±\$254\$138±\$317 Total\$2,202±\$1,512\$2,596±\$1,745\$3,244±\$2,832Non-biologic DMARDs\* Count0.4±0.5±0.4±0.50.5±0.5 Cost\$16±\$39±\$13±\$29\$15±\$28Other RA Prescriptions\*\* Count1.1±1.0±1.0±1.01.1±1.4 Cost\$78±\$301±\$48±\$124\$50±\$165Total RA-related healthcare resource utilization Insurer-paid\$2,668±\$3,547\$2,771±\$1,974\$3,542±\$3,667 Patient-paid\$147±\$199\$165±\$269\$178±\$344 Total\$2,815±\$3,615\$2,936±\$2,038\$3,720±\$3,713Healthcare costs were expressed in 2011 constant US dollars*ABA* abatacept, *INF* infliximab, *RA* rheumatoid arthritis, *SD* standard deviation, *TCZ* tocilizumab\* Non-biologic DMARDs include methotrexate, hydroxychloroquine, leflunomide, minocycline, sulfasalazine, cyclosporine, azathioprine, and gold sodium thiomalate\*\* Other RA prescriptions include non-steroidal anti-inflammatory drugs, corticosteroids, and other analgesics

Table [4](#Tab4){ref-type="table"} displays unadjusted PPPM all-cause healthcare utilization and costs. The mean PPPM (SD) total all-cause healthcare costs were \$3,667 (\$4,044) for tocilizumab-treated patients, \$3,842 (\$3,426) for abatacept-treated patients, and \$4,739 (\$6,058) for infliximab-treated patients. As with RA-related healthcare costs, the majority of all-cause costs were driven by the cost of the biologic, which is captured in the 'other outpatient services' category.Table 4Unadjusted per-patient per-month all-cause healthcare utilization and costsTCZ (*N* = 1,090)ABA (*N* = 1,759)INF (*N* = 922)MeanSDMeanSDMeanSDInpatient admissions Count0.0±0.10.0±0.10.0±0.1 Cost\$415±\$3,353\$316±\$2,457\$505±\$4,414Emergency room visits Count0.1±0.20.1±0.20.1±0.2 Cost\$33±\$130\$41±\$265\$42±\$254Outpatient office visits Count1.5±1.01.4±1.01.4±1.2 Cost\$142±\$150\$126±\$109\$131±\$114Other outpatient services Count9.2±5.39.1±6.09.6±7.0 Cost\$2,701±\$1,762\$3,008±\$1,923\$3,727±\$3,927Outpatient prescription claims Count4.3±3.24.0±3.14.1±3.2 Cost\$376±\$593\$350±\$672\$334±\$688Total healthcare resource utilization Insurer-paid\$3,428±\$3,959\$3,590±\$3,345\$4,468±\$6,009 Patient-paid\$239±\$237\$252±\$306\$270±\$375 Total\$3,667±\$4,044\$3,842±\$3,426\$4,739±\$6,058Healthcare costs were expressed in 2011 constant US dollars*ABA* abatacept, *INF* infliximab, *SD* standard deviation, *TCZ* tocilizumab

Figure [2](#Fig2){ref-type="fig"} displays multivariable-adjusted PPPM biologic, RA-related, and all-cause healthcare costs. When compared with abatacept-treated patients, tocilizumab-treated patients had mean (95 % confidence interval) multivariable-adjusted healthcare costs that were \$703 (608--798) lower for biologic costs, \$692 (550--834) lower for RA-related costs, and \$693 (485--900) lower for all-cause costs (all *P* \< 0.05) (Table [5](#Tab5){ref-type="table"}). When compared with infliximab-treated patients, tocilizumab-treated patients had mean (95 % confidence interval) multivariable-adjusted healthcare costs that were \$1,246 (1,074--1,418) lower for biologic costs, \$1,362 (1,123--1,601) lower for RA-related costs, and \$1,558 (1,153--1,964) lower for all-cause costs (all *P* \< 0.05).Fig. 2Multivariable-adjusted (see Table [5](#Tab5){ref-type="table"}) per-patient per-month healthcare costs. *ABA* abatacept, *INF* infliximab, *RA* rheumatoid arthritis, *TCZ* tocilizumabTable 5Multivariable-adjusted per-patient per-month cost differencesMultivariable-adjusted\* mean (95 % confidence interval) per-patient per-month cost difference\*\*ABA minus TCZINF minus TCZBiologic costs\$703 (608--798)\$1,246 (1,074--1,418)RA-related healthcare costs\$692 (550--834)\$1,362 (1,123--1,601)All-cause healthcare costs\$693 (485--900)\$1,558 (1,153--1,964)*ABA* abatacept, *INF* infliximab, *RA* rheumatoid arthritis, *TCZ* tocilizumab\* The multivariable models adjusted all variables listed in Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"} (median follow-up excepted); adjusted costs are based on predictions set at the cohort-level mean values of continuous covariates and the base values of categorical covariates\*\* All cost differences were statistically significant at *P* \< 0.05

Discussion {#Sec11}
==========

To our knowledge, this study is the first to compare healthcare costs between RA patients treated with infused biologics after previously using at least one other biologic agent. We found that among such patients, those treated with tocilizumab had the lowest real-world healthcare costs, largely driven by lower costs directly related to biologic treatment.

Owing to the uniqueness of the present study's data, there are very few studies to which ours can be compared. Wong et al. \[[@CR20]\] used data from 72 US medical clinics to examine the drug and administration costs for abatacept, infliximab, and rituximab among RA patients initiating treatment between January 1, 2006 and December 31, 2008. They reported that mean (SD) unadjusted total costs per infusion visit were \$1,827 (\$622) for abatacept, \$2,828 (\$1,282) for infliximab, and \$6,076 (\$1,689) for rituximab. Though the reported trend of infliximab being more costly than abatacept on a per-visit basis is consistent with the present study's findings on these two biologics, the study's cost comparisons were substantially confounded by the differences in the frequency of administration of the studied agents, which were unaccounted for in the per-visit cost comparisons. For example, abatacept is administered at 0, 2, and 4 weeks, and then every 4 weeks thereafter; infliximab, is administered at 0, 2, and 6 weeks, and then every 4--8 weeks thereafter; and rituximab is administered as two infusions separated by 2 weeks every 24 weeks or on the basis of clinical evaluation, but not sooner than every 16 weeks \[[@CR5]--[@CR7]\]. Thus, the data from Wong et al. \[[@CR20]\] are difficult to interpret when trying to understand total drug and administration costs that would be expected while a patient is being treated with infused agents.

In another prior study, Bonafede et al. \[[@CR31]\] estimated annual biologic treatment costs for subcutaneous and infused biologics using a unit-cost approach, also finding differences among the infused biologic agents abatacept, infliximab, and rituximab. Results from the study were also somewhat consistent with the present analyses in that they, too, associated abatacept with lower average annual costs than infliximab (\$16,738 vs. \$21,273, respectively). The analyses were intended to be purely descriptive, however, and made no attempts to adjust for inherent differences in patient characteristics that may drive differences in healthcare costs \[[@CR21]\].

In one of the only other studies to report cost data for tocilizumab, Liu et al. \[[@CR21]\] performed an indirect analysis of cost per responder in RA using clinical trial data and published drug acquisition and administration costs for FDA-approved RA biologics. They estimated that among the infused therapies, tocilizumab had the numerically lowest mean (95 % confidence interval) cost per responder at \$31,363 (14,713--64,232), compared with \$50,496 (25,819--92,069) for infliximab and \$61,088 (34,791--104,295) for abatacept. Though these data are consistent with the present study's findings regarding tocilizumab, it is important to consider that Liu et al.'s results were based on a simulation as opposed to being based upon actual observational data.

In the present study, the majority of all-cause costs were accounted for by the biologic therapies, suggesting that the real-world patterns of use of these therapies may be amongst the most important cost drivers for RA patients. The PPPM number of administrations for infliximab was 1.0; the expected number of administrations per month would be closer to 0.5 if infliximab were administered every 8 weeks as recommended for most patients on label. Thus, even after accounting for the more frequent induction doses (0, 2, 6 weeks), these higher than expected PPPM administrations suggest that dose escalation in the form of more frequent administration was occurring for infliximab. This is consistent with prior analyses that have suggested that dose escalation happens frequently in infliximab \[[@CR11], [@CR15], [@CR17]--[@CR19], [@CR32]\]. While abatacept does not have a labeled option for dose escalation, tocilizumab may be prescribed at either 4 mg/kg every 4 weeks or 8 mg/kg every 4 weeks on the basis of clinical response \[[@CR5], [@CR8]\].

In a post hoc exploratory analysis of tocilizumab-treated patients, we attempted to estimate the proportion that dose escalated from 4 mg/kg to 8 mg/kg on the basis of changes in paid claim amounts. The Kaplan-Meier estimated probability of dose escalation from 4 mg/kg to 8 mg/kg within 1 year after initiation of tocilizumab was approximately 75 %. Given the relatively short follow-up of the present study (median ranging from 251 days in infliximab-treated patients to 280 days in abatacept-treated patients), further research should look at longer-term cost comparisons, which may be different from those reported in the present study, depending on the dosing patterns for each drug.

This study was subject to limitations. Procedure and diagnosis coding on administrative claims data are recorded by healthcare practitioners to support reimbursement. Measurement error can result from miscoded or non-coded administrative claims. For example, claims related to RA may not have been coded with an RA diagnosis code, thereby potentially underestimating the costs of RA. Though this study used multivariable analyses to adjust for differences in measurable patient characteristics between the infused biologics, we cannot rule out the possibility of residual confounding. Because of data limitations, we were unable to discern the exact line of therapy each patient was receiving. Compared with patients who are in earlier lines of biologic therapy, patients who have previously failed several biologics may be more refractory and may have higher RA-related costs, all-cause costs, and higher biologic-related costs in part due to more dose escalation \[[@CR32]\]. This study only compared the healthcare costs from a US payer perspective and did not compare the clinical effectiveness of the different treatments. Administrative claims data do not provide information on clinical outcomes such as tender/swollen joint counts, pain, and physical function (among others). Thus, we could not assess the comparative clinical effectiveness of these therapies. Furthermore, the database does not have information on weight, which affects the total dose given to patients. However, using persistence on therapy as a proxy for effectiveness, our previous research has shown that tocilizumab patients had better persistence than patients receiving infliximab and abatacept \[[@CR33]\]. Finally these results are not generalizable to the entire US RA population, including those who are uninsured or insured through Medicaid.

Conclusion {#Sec12}
==========

Among RA patients treated with infused biologics after previously using at least one other biologic, patients treated with tocilizumab had the lowest real-world healthcare costs, largely driven by lower costs directly related to biologic treatment. Such biologic-related cost differences may be driven by variations in real-world treatment patterns (e.g., dose, treatment frequency, dose escalation).
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